Omarigliptin

Omarigliptin

Chemical structure of Omarigliptin

Omarigliptin is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones in the body. These hormones help to regulate blood glucose levels by increasing insulin release and decreasing glucagon levels.

Mechanism of Action

Omarigliptin functions by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the degradation of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By inhibiting DPP-4, omarigliptin prolongs the action of these hormones, thereby enhancing insulin secretion and reducing glucagon release in a glucose-dependent manner.

Pharmacokinetics

Omarigliptin is administered orally and is known for its once-weekly dosing schedule, which is a result of its long half-life. This makes it a convenient option for patients who may have difficulty adhering to daily medication regimens. The drug is absorbed in the gastrointestinal tract and is metabolized primarily in the liver.

Clinical Use

Omarigliptin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin to achieve better glycemic control. It is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Side Effects

Common side effects of omarigliptin include nasopharyngitis, headache, and upper respiratory tract infection. As with other DPP-4 inhibitors, there is a potential risk of pancreatitis and hypersensitivity reactions. Patients should be monitored for signs and symptoms of these conditions.

Contraindications

Omarigliptin is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with a history of pancreatitis.

Related Pages

• Type 2 diabetes mellitus
• DPP-4 inhibitors
• Incretin hormones
• Insulin